Burroughs Wellcome Retrovir
Temporary distribution system, set up initially to ensure that the limited supply of AZT would reach target population of AIDS and advanced ARC patients, will be discontinued ahead of schedule. At the time of the drug's approval in March, Burroughs Wellcome said it would dissolve the elaborate distribution system once the company had enough drug to meet demand. Last spring, B-W predicted supply levels would not reach enough for 30,000 patients until year end; however, the company now says it can treat 50,000 patients.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.